Role of dopamine D1 receptors in the striatal and cortical fos expression induced by the muscarinic agonist pilocarpine

European Journal of Pharmacology

Volumn 488, Issue 1-3, 2004, Pages 85-90

  Wirtshafter, David ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Acetylcholine; C fos; Caudate; Dopamine D1 receptor; Immediate early gene; Striatum

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; PILOCARPINE; PROTEIN FOS; SCOPOLAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; IMMEDIATE EARLY GENE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; CEREBRAL CORTEX; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENES, FOS; IMMUNOHISTOCHEMISTRY; MALE; MUSCARINIC AGONISTS; NEOSTRIATUM; PILOCARPINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, MUSCARINIC;

EID: 1642275319     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.02.025     Document Type: Article

References (35)

1. al-Tajir G., Starr M. Disordered dopamine neurotransmission in the striatum of rats undergoing pilocarpine-induced generalized seizures, as revealed by microdialysis. J. Neural Transm., Parkinson's Dis. Dement. Sect. 5:1993;89-100.
2. Bernard V., Dumartin B., Lamy E., Bloch B. Fos immunoreactivity after stimulation or inhibition of muscarinic receptors indicates anatomical specificity for cholinergic control of striatal efferent neurons and cortical neurons in the rat. Eur. J. Neurosci. 5:1993;1218-1225.
3. Bymaster F.P., Wong D.T., Mitch C.H., Ward J.S., Calligaro D.O., Schoepp D.D., Shannon H.E., Sheardown M.J., Olesen P.H., Suzdak P.D., Swedberg D.B., Sauerberg P. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232). J. Pharmacol. Exp. Ther. 269:1994;282-289.
4. Calabresi P., Centonze D., Gubellini P., Pisani A., Bernardi G. Acetylcholine-mediated modulation of striatal function. T.I.N.S. 23:2000;120-126.
5. Cook D.F., Wirtshafter D. Quinpirole attenuates striatal c-fos induction by serotonin, opioid and muscarinic receptor agonists. Eur. J. Pharmacol. 349:1998;41-47.
6. Day J., Fibiger H.C. Dopaminergic regulation of cortical acetylcholine release. Synapse. 12:1992;281-286.
7. Di Chiara G., Morelli M. Acetylcholine, dopamine and NMDA transmission in the caudate-putamen: their interactions and function as a striatal modulatory system. Percheron G., McKenzie J.S., Feger J. The Basal Ganglia. vol. IV:1994;491-505 Plenum, New York.
8. Fink-Jensen A., Kristensen P., Shannon H.E., Calligaro D.O., Delapp N.W., Whitesitt C., Ward J.S., Thomsen C., Rasmusseen T., Sheardown M.J., Jeppesen L., Sauerberg P., Bymaster F.P. Muscarinic agonists exhibit functional dopamine antagonism in unilaterally 6-OHDA lesioned rats. NeuroReport. 9:1988;3481-3486.
9. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. J. Neural Transm., Suppl. 36:1992;43-59.
10. Gerfen C.R., Kitai S.T. Intrastriatal administration of the muscarinic antagonist scopolamine: effects on D2 dopamine receptor antagonist-induced behavior and gene expression in striatal neurons. Abstr. - Soc. Neurosci. 23:1997;745.
11. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. T.I.N.S. 13:1990;244-254.
12. Guo N., Robertson G.S., Fibiger H.C. Scopolamine attenuates haloperidol-induced c-fos expression in the striatum. Brain Res. 588:1992;164-167.
13. Hernandez-Lopez S., Gongora-Alfaro J.L., Martinez-Fong D., Aceves J. A cholinergic input to the substantia nigra pars compacta increases striatal dopamine metabolism measured by in vivo voltammetry. Brain Res. 598:1992;114-120.
14. Hughes P., Dragunow M. Muscarinic receptor-mediated induction of Fos protein in rat brain. Neurosci. Lett. 150:1993;122-126.
15. Hughes P., Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol. Rev. 47:1995;133-178.
16. Hussain N., Flumerfelt B.A., Rajakumar N. Muscarinic, adenosine A2 and histamine H3 receptor modulation of haloperidol-induced C-FOS expression in the striatum and nucleus accumbens. Neuroscience. 112:2002;427-438.
17. Kane M.C., Wirtshafter D. The m2/m4 muscarinic receptor agonist BuTAC attenuates dopamine agonist-induced behaviors. Abstr. - Soc. Neurosci. 2002;682.9.
18. Kemel M.L., Gauchy C., Desban M., Krebs M.O., Glowinski J. Control of dopamine release by acetylcholine and dynorphin in the striosomal and matrix compartments of the cat caudate nucleus. Neurochem. Int. 20:1992;111s-114s. (Suppl.).
19. Klemm W.E. Experimental catalepsy is both enhanced and disrupted by apomorphine. Psychopharmacology. 87:1987;12-15.
20. Le Moine C., Normand E., Bloch B. Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene. Proc. Natl. Acad. Sci. U. S. A. 88:1991;4205-4209.
21. MacGibbon G.A., Lawlor P.A., Hughes P., Young D., Dragunow M. Differential expression of inducible transcription factors in basal ganglia neurons. Mol. Brain Res. 34:1995;294-302.
22. Marchi M., Volpe G., Augliera A., Codignola A., Lunardi G., Raiteri M. Cholinergic modulation of dopamine release in corpus striatum and substantia nigra of the rat. Neurochem. Int. 20:1992;271S-274S. (Suppl.).
23. Mason S.T., Roberts D.C.S., Fibiger H.C. Noradrenergic influences on catalepsy. Psychopharmacology. 60:1978;53-57.
24. McCormick D.A. Neurotransmitter actions in the thalamus and cerebral cortex. J. Clin. Neurophysiol. 9:1992;212-223.
25. Merchant K.M., Dorsa D.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc. Natl. Acad. Sci. U. S. A. 90:1993;3447-3451.
26. Millan M.H., Patel S., Meldrum B.S. Olfactory bulbectomy protects against pilocarpine-induced motor limbic seizures in rats. Brain Res. 398:1986;204-206.
27. Miwa H., Nishi K., Fuwa T., Mizuno Y. Differential expression of c-Fos following administration of two tremorgenic agents: harmaline and oxotremorine. NeuroReport. 11:2000;2385-2390.
28. Raiteri M., Leardi R., Marchi M. Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain. J. Pharmacol. Exp. Ther. 228:1984;209-214.
29. Robertson H.A., Paul M.L., Moratalla R., Graybiel A.M. Expression of the immediate early gene c-fos in basal ganglia: induction by dopaminergic drugs. Can. J. Neurol. Sci. 19:1991;380-383.
30. Smolders I., Bogaert L., Ebinger G., Michotte Y. Muscarinic modulation of striatal dopamine, glutamate, and GABA release, as measured with in vivo microdialysis. J. Neurochem. 68:1997;1942-1948.
31. Steiner H., Kitai S.T. Regulation of rat cortex function by D1 dopamine receptors in the striatum. J. Neurosci. 20:2000;5449-5460.
32. Turski L., Cavalheiro E.A., Sieklucka-Dziuba M., Ikonomidou-Turski C., Czuczwar S.Z., Turski W.A. Seizures produced by pilocarpine: neuropathological sequelae and activity of glutamate decarboxylase in the rat forebrain. Brain Res. 398:1986;37-48.
33. Wang J.Q., McGinty J.F. Scopolamine augments c-fos and zif/268 messenger RNA expression induced by the full D1 dopamine receptor agonist SKF-82958 in the intact rat striatum. Neuroscience. 72:1996;601-616.
34. Wirtshafter D., Asin K.E. Interactive effects of stimulation of D1 and D2 dopamine receptors on Fos-like immunoreactivity in the normosensitive rat striatum. Brain Res. Bull. 35:1994;85-91.
35. Wirtshafter D., Asin K.E. Comparative effects of scopolamine and quinpirole on the striatal Fos expression induced by stimulation of D1 dopamine receptors in the rat. Brain Res. 893:2001;202-214.